Alpha tocopherol
PreclinicalSmall molecule
Alpha tocopherol is one of 41 small molecule programs targeting Oxidative Stress. It is currently in Preclinical.
2
Indications
8
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
51 competitors in Oxidative Stress
#DrugCompanyPhaseTrials
1Amaryl
SanofiApproved
Precose
BayerApproved
Amidate
PfizerApproved
Actos
TakedaApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Zocor
OOrganon and Co
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Kidney Disease1 trial
3 more indications
Tetralogy of Fallot1 trial
Effect of Parenteral Alpha-Tocopherol in the Definitive Surgery of Tetralogy of Fallot
Completed·—·Phase 1·NCT07194304·60 enrolled
Diabetes1 trial
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT00862433·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alpha tocopherol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TThammasat University